Traws Pharma is a clinical-stage biotech whose drug candidates are aimed at oncology and neurological indications, and it has no commercial product revenue to speak of. The company reports revenue growth of -100.0% and a return on equity of -433.4%, which describes a business still burning capital against a very small balance sheet, with a market capitalisation of about $6 million. The thesis rests entirely on whether any of its pipeline assets can reach human proof-of-concept data and then attract a partner or financing on acceptable terms. Those are binary events that the current figures do not yet reflect, and the score of 23/100 and absence from any index memberships both point to a name the house screens rate as weak on quality and liquidity. It warrants a deeper look only if the pipeline catalysts and cash runway can be verified from filings, since the headline numbers alone give little reason to spend more time on it.
Plain-English pros, cons, and what to watch. Pro feature.
See what each model says, the assumptions behind it, the bad, normal and good cases, and why the fair value changed.
The full quality picture: a reason under every score, how the scores moved, and the conviction breakdown.
The full analyst picture: the price-target distribution against the current price, forward consensus estimates, and how ACCE's own models compare.
Trades are only made public after a delay. We show the delay so you know how old the news is.
Follow the informed money: 13F position changes, insider and Congress trades, and 13D activist filings.
| Date | Type | New | Previous | Price |
|---|---|---|---|---|
| 15 Oct 2026, 00:00 CEST | ACCE price target | $0.20 | first publication | $0.41 |
Answered from Traws Pharma Inc. Common Stock fundamentals + recent valuations. Every number shows its source and date.
| Company | Price | Fair value | vs fair value | P/E | ROE | Quality | Score |
|---|---|---|---|---|---|---|---|
| TRAW Traws Pharma Inc. Common Stock | $0.34 | - | - | - | -433.4% | 29 | 23 |
| ZEAL.CO Zealand Pharma A/S | kr 226.00 | - | - | 5.8x | 16.3% | 90 | 51 |
| BIOA-B.ST BioArctic AB (publ) | kr 300.00 | kr 259 | 16% above | 254.2x | 5.2% | 62 | 38 |
| BAVA.CO Bavarian Nordic A/S | kr 247.40 | kr 257 | 4% below | 12.7x | 12.2% | 86 | 86 |
| CAMX.ST Camurus AB (publ) | kr 666.00 | kr 325 | 105% above | 58.8x | 15.9% | 90 | 55 |
| BIOCON.NS Biocon Limited | ₹323.50 | - | - | 97.7x | - | 67 | 52 |
| KRYS Krystal Biotech Inc. Common Stock | $311.50 | $153 | 104% above | 40.1x | 20.1% | 95 | 71 |
Where TRAW ranks against its sector peers on each metric.